Loading patent…
AssigneeBeiGene, Ltd.
InventorsRenke Li, Xiaoyan Tang, Mengran Qian, Jie Pan, Zhao Zhao, Xi Wu, Ming Jiang, Hui Li, Xiaona Sun, Yanzhou Zhang, Mengmeng Lu, Yun Chen
Estimating the term…
The present disclosure provides for antibody or antigen-binding fragment thereof that specifically binds to human cMET and multispecific antibody or antigen-binding fragment thereof, comprising a first antigen binding domain that specifically binds a first epitope of human cMET; a second antigen binding domain that specifically binds to a second epitope of human cMET; and a third antigen binding domain that specifically binds to human EGFR; wherein the first epitope is distinct from the second epitope, or wherein the first antigen binding domain does not compete with the second antigen binding domain. The present disclosure also provides for the use of the antibodies or multispecific antibodies for treating a disease, such as cancer.
An antibody or antigen-binding fragment thereof which specifically binds human cMET, comprising:
-6. (canceled)
A multispecific antibody or antigen-binding fragment thereof, comprising a first antigen binding domain that specifically binds a first epitope of human cMET, and a second antigen binding domain that specifically binds to a second epitope of human cMET, wherein the first antigen binding domain that specifically binds to the first epitope of human cMET comprises:
-64. (canceled)
A multispecific antibody or antigen-binding fragment thereof, comprising a first antigen binding domain that specifically binds to a first epitope of human cMET:
68-69. (canceled)
(canceled)
74-75. (canceled)
77-78. (canceled)
80-84. (canceled)
87-108. (canceled)
A multispecific antibody or antigen-binding fragment thereof, comprising a first polypeptide, a second polypeptide, and a third polypeptide, wherein
Dependencies are inferred from the claim text.